Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 18/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | CYP2E1 | P05181 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.49 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6499533 | 0.96 | OPRL1 (0.92) | OPRL1CYP1A2CYP2E1CYP3A4CYP2C8 | |
| SCHEMBL6484371 | 0.87 | OPRL1 (0.77) | OPRL1CYP1A2CYP2E1CYP3A4CYP2C8 | |
| SCHEMBL6484363 | 0.85 | OPRL1 (0.74) | OPRL1CYP1A2CYP2E1CYP3A4CYP2C8 | |
| Hydrochloric Acid SCHEMBL6493457 | 0.76 | OPRL1 (0.62) | OPRL1 | |
| Hydrochloric Acid SCHEMBL6493445 | 0.74 | OPRL1 (0.59) | OPRL1CYP1A2CYP2E1CYP3A4CYP2C8 | |
| SCHEMBL6496854 | 0.74 | OPRL1 (0.59) | OPRL1CYP1A2CYP2E1CYP3A4CYP2C8 | |
| Hydrochloric Acid SCHEMBL6528008 | 0.74 | OPRL1 (0.98) | OPRL1 | |
| SCHEMBL6484002 | 0.73 | OPRL1 (0.58) | OPRL1 | |
| SCHEMBL6496850 | 0.72 | OPRL1 (0.56) | OPRL1CYP1A2CYP2E1CYP3A4CYP2C8 | |
| SCHEMBL8069366 | 0.71 | OPRL1 (0.66) | OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6969712-B2 | Benzimidazole derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-11-29 | — | — | US | disclosed |
| US-20040044056-A1 | Benzimidazole derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-03-04 | — | — | US | disclosed |
| EP-1342717-A1 | BENZIMIDAZOLE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2003-09-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044056-A1 | Benzimidazole derivatives | GPR119, OPRL1, INSR | OPRL1 2/4885CYP1A2 2078/4885CYP2E1 2284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.